• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Impact of Anti-Tumor Necrosis Factor and Thiopurine Medications on the Development of COVID-19 in Patients With Inflammatory Bowel Disease: A Nationwide Veterans Administration Cohort Study.抗肿瘤坏死因子和硫嘌呤类药物对炎症性肠病患者感染新型冠状病毒肺炎的影响：一项全国退伍军人事务部队列研究
Gastroenterology. 2020 Oct;159(4):1545-1546.e1. doi: 10.1053/j.gastro.2020.05.065. Epub 2020 May 29.
2
Adherence of Infusible Biologics During the Time of COVID-19 Among Patients With Inflammatory Bowel Disease: A Nationwide Veterans Affairs Cohort Study.炎症性肠病患者在 COVID-19 期间可输注生物制剂的依从性：一项全国性退伍军人事务队列研究。
Gastroenterology. 2020 Oct;159(4):1592-1594.e1. doi: 10.1053/j.gastro.2020.06.044. Epub 2020 Jun 20.
3
Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease.炎症性肠病患者 COVID-19 的流行病学及治疗对结局的影响。
Am J Gastroenterol. 2020 Oct;115(10):1722-1724. doi: 10.14309/ajg.0000000000000830.
4
Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.炎症性肠病中的硫嘌呤：新发现与新视角。
J Crohns Colitis. 2018 Apr 27;12(5):610-620. doi: 10.1093/ecco-jcc/jjx181.
5
Risk of Severe Coronavirus Disease 2019 in Patients With Inflammatory Bowel Disease in the United States: A Multicenter Research Network Study.美国炎症性肠病患者发生重症2019冠状病毒病的风险：一项多中心研究网络研究
Gastroenterology. 2020 Oct;159(4):1575-1578.e4. doi: 10.1053/j.gastro.2020.06.003. Epub 2020 Jun 6.
6
COVID-19 and implications for thiopurine use.2019冠状病毒病及其对硫唑嘌呤使用的影响。
Med J Aust. 2020 Jun;212(10):490-490.e1. doi: 10.5694/mja2.50613. Epub 2020 May 13.
7
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.如何在 COVID-19 时代处理自身免疫性风湿和炎症性肠病患者：专家意见。
Autoimmun Rev. 2020 Jul;19(7):102574. doi: 10.1016/j.autrev.2020.102574. Epub 2020 May 5.
8
Managing Uveitis during the COVID-19 Pandemic.在新冠疫情期间管理葡萄膜炎
Ophthalmology. 2020 Sep;127(9):e65-e67. doi: 10.1016/j.ophtha.2020.05.037. Epub 2020 May 19.
9
Thiopurine Metabolism in the Era of Combotherapy.联合治疗时代的硫嘌呤代谢
Inflamm Bowel Dis. 2016 Jun;22(6):1496-501. doi: 10.1097/MIB.0000000000000737.
10
Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis.日本炎症性肠病患者使用硫唑嘌呤或生物制剂不会增加淋巴瘤风险：一项大规模行政数据库分析。
J Crohns Colitis. 2020 Jun 19;14(5):617-623. doi: 10.1093/ecco-jcc/jjz204.

引用本文的文献

1
Navigating SARS-CoV-2-related immunopathology in Crohn's disease: from molecular mechanisms to therapeutic challenges.探讨克罗恩病中与 SARS-CoV-2 相关免疫病理学：从分子机制到治疗挑战。
Virol J. 2024 Nov 13;21(1):288. doi: 10.1186/s12985-024-02529-1.
2
The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-IBD in Seniors.2023年炎症性肠病在加拿大的影响：特殊人群——老年人中的炎症性肠病
J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S45-S54. doi: 10.1093/jcag/gwad013. eCollection 2023 Sep.
3
The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.皮肤科疾病免疫调节治疗对感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）风险及与冠状病毒病（COVID-19）相关结局的影响
Curr Dermatol Rep. 2023;12(2):45-55. doi: 10.1007/s13671-023-00385-w. Epub 2023 Apr 3.
4
COVID-19 vaccination in adults with inflammatory bowel disease.炎症性肠病成年患者的新冠病毒疫苗接种
Therap Adv Gastroenterol. 2023 May 22;16:17562848231173130. doi: 10.1177/17562848231173130. eCollection 2023.
5
A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.一种针对 SARS-CoV-2 的嵌合抗原受体 T 细胞模型鉴定出非洛地平、法舒地尔、伊马替尼和卡泊芬净可能是治疗致命性 COVID-19 的药物。
Cell Mol Immunol. 2023 Apr;20(4):351-364. doi: 10.1038/s41423-023-00985-3. Epub 2023 Mar 2.
6
Risk of COVID-19 Infection After Full Immunization in Patients With Inflammatory Bowel Disease on Treatment: A Research Network Analysis.炎症性肠病患者在接受治疗期间全程免疫后感染新型冠状病毒肺炎的风险：一项研究网络分析
Cureus. 2023 Jan 20;15(1):e34004. doi: 10.7759/cureus.34004. eCollection 2023 Jan.
7
Susceptibility of Patients with Inflammatory Bowel Disease to COVID-19 Compared with Their Households.炎症性肠病患者与家庭成员相比对COVID-19的易感性。
Middle East J Dig Dis. 2022 Apr;14(2):182-191. doi: 10.34172/mejdd.2022.271. Epub 2022 Apr 30.
8
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII).炎症性肠病中新冠病毒病的危险因素：一项基于西班牙炎症性肠病注册数据库（ENEIDA）的全国性病例对照研究（COVID-19-EII）
J Clin Med. 2022 Dec 19;11(24):7540. doi: 10.3390/jcm11247540.
9
COVID-19 and inflammatory bowel disease crosstalk: From emerging association to clinical proposal.COVID-19 与炎症性肠病的相互作用：从新出现的关联到临床建议。
J Med Virol. 2022 Dec;94(12):5640-5652. doi: 10.1002/jmv.28067. Epub 2022 Aug 24.
10
The Impact of Inflammatory Bowel Diseases and Related Medications on COVID-19 Severity and Outcome: A Tertiary Referral Center Experience from Turkey.炎症性肠病及其相关药物对 COVID-19 严重程度和结局的影响：来自土耳其的一家三级转诊中心的经验。
Turk J Gastroenterol. 2022 Dec;33(12):1025-1032. doi: 10.5152/tjg.2022.22059.

本文引用的文献

1
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.皮质类固醇，而不是 TNF 拮抗剂，与炎症性肠病患者 COVID-19 不良结局相关：来自国际登记处的结果。
Gastroenterology. 2020 Aug;159(2):481-491.e3. doi: 10.1053/j.gastro.2020.05.032. Epub 2020 May 18.
2
2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases.2019 新型冠状病毒病（COVID-19）合并炎症性肠病患者。
Aliment Pharmacol Ther. 2020 Jul;52(2):276-283. doi: 10.1111/apt.15804. Epub 2020 Jun 7.
3
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.免疫介导性炎症疾病中的新冠病毒病——来自纽约的病例系列
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
4
A novel coronavirus outbreak of global health concern.一场引发全球卫生关注的新型冠状病毒疫情。
Lancet. 2020 Feb 15;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24.
5
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.炎症性肠病治疗相关的严重和机会性感染风险。
Gastroenterology. 2018 Aug;155(2):337-346.e10. doi: 10.1053/j.gastro.2018.04.012. Epub 2018 Apr 12.
6
Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.总体和比较风险的带状疱疹与药物治疗炎症性肠病：一项全国性队列研究。
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1919-1927.e3. doi: 10.1016/j.cgh.2017.12.052. Epub 2018 Jan 5.

Impact of Anti-Tumor Necrosis Factor and Thiopurine Medications on the Development of COVID-19 in Patients With Inflammatory Bowel Disease: A Nationwide Veterans Administration Cohort Study.

作者信息

Khan Nabeel, Patel Dhruvan, Xie Dawei, Lewis James, Trivedi Chinmay, Yang Yu-Xiao

机构信息

Division of Gastroenterology, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania; Division of Gastroenterology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania.

Division of Gastroenterology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania.

出版信息

Gastroenterology. 2020 Oct;159(4):1545-1546.e1. doi: 10.1053/j.gastro.2020.05.065. Epub 2020 May 29.

DOI:10.1053/j.gastro.2020.05.065
PMID:32479823
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7258834/
Abstract
摘要